Children with definitive confirmatory eligible histologic or cytological diagnosis of eligible CNS tumor within the brain or spinal cord, who have not previously received either irradiation or chemotherapy (except corticosteroids) will be eligible for study entry
Patients with >= grade  hypothyroidism due to history of autoimmunity are not eligible; note: hypothyroidism due to previous irradiation on thyroidectomy will not impact eligibility
Patients must be accessible for treatment and follow-up. Patients registered on this trial must receive protocol treatment and be followed at the participating center. This implies there must be reasonable geographical limits placed on patients being considered for this trial. Investigators must ensure that the patients randomized on this trial will be available for complete documentation of the treatment, response assessment, adverse events, and follow-up.
Patients with grade  ataxia or grade > extrapyramidal movement disorder are not eligible
Patients (at National Cancer Institute [NCI] Community Oncology Research Program [NCORP] Institutions only) must be offered the opportunity to participate in the S-E Behavioral and Health Outcomes study (BAHO); NOTE: patients who have already started endocrine therapy are eligible for the BAHO study
Patients with clinically controlled thyroiditis or pituitary disorders on stable replacement therapy are eligible
Patients with rheumatoid arthritis and other arthropathies, Sjogrens syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
Patients with pathologic staging of ypN(i+) or ypN(mol+) are eligible
For patients with known molecular alterations, institution has been notified that patient is deemed eligible for Arm T per review of molecular testing reports
REGISTRATION STEP -RANDOMIZATION: Patients must be eligible for at least one of the currently active investigational treatment arms (SB or SC); if the patient does not meet eligibility criteria for at least one active investigational arm, then the patient is not eligible for S
Patients with multifocal or multicentric invasive disease are eligible as long as all the lesions for which HER characterization is available are HER negative
Patients enrolled on AALL, with Down syndrome, meeting the following criteria will NOT be eligible to continue on AALL but WILL BE eligible to enroll on the DS HR B-ALL stratum of this study at the end of Induction: \r\n* Day  MRD >= .%\r\n* MLL rearrangement\r\n* Hypodiploidy (n <  chromosomes and/or DNA index < .)
Patients must be newly diagnosed with histologically confirmed intracranial ependymoma; patients with classic ependymoma (WHO II) or anaplastic ependymoma (WHO III) are eligible, as are various subtypes described as clear cell, papillary, cellular or a combination of the above
Patients with pre-existing significant central nervous system pathology that would preclude treatment with blinatumomab, including: history of severe brain injury, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination/movement disorder, or autoimmune disease with CNS involvement are not eligible; patients with a history of cerebrovascular ischemia/hemorrhage with residual deficits are not eligible; (patients with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved)
Patients with disease limited to the skin are not eligible, regardless of how wide-spread
Patients with known active cutaneous squamous cell carcinoma (includes keratoacanthoma or mixed keratoacanthoma subtype) are not eligible; patients who have fully excised lesions with dermatologic confirmation of absence of disease are eligible
No late relapse with completely surgically resectable disease; patients with late relapses (defined as relapse >=  years from the date of completion of the last chemotherapy regimen) whose disease is completely surgically resectable are not eligible; patients with late relapses who have unresectable disease are eligible
Patients who have received prior therapy with a specific inhibitor of TRK (including but not limited to entrectinib [RXDX-], DS-b, and PLX) are not eligible
Patients with subependymal giant cell astrocytomas (SEGAs) are not eligible
Patient must be eligible for treatment with nivolumab; patients previously treated with nivolumab, pembrolizumab or atezolizumab and who have progressed are eligible; patients with targetable with EGFR or ALK mutations are eligible after disease recurrence or progression after at least one targeted therapy for advanced or metastatic disease
HER+ and HER- patients are eligible
All patients must have diagnostic laparoscopy with diagnostic washings for cytology; both cytology positive and negative patients are eligible for enrollment, but only cytology negative patients will be included in the primary analyses; gross peritoneal disease is not eligible
Patients allergic to eggs are not eligible
Cystoscopically and radiographically confirmed cT-a cN cM disease. Patients with cTa disease invading into the prostatic stroma with no cystoscopic confirmation of muscle invasion are eligible.
Participants eligible for taxane monotherapy
All hematologic, gastrointestinal, and genitourinary chemotherapy toxicities must be less than Grade  at the time study therapy is to begin. (Note: Transfusions may be used to correct hemoglobin for patients experiencing anemia from therapy who otherwise would be eligible for the study.
Patients must have measurable disease and be eligible to receive nivolumab in combination with ipilimumab treatment per institutional guidelines
Previous treatment with investigational agents that inhibit MDM or MDMX activity (some MDM-treated patients may be eligible)
Patients with tuberculosis (TB). Note: Patient with latent TB may be eligible based on the investigator's benefit-risk assessment.
Patients with TB. Note: Patient with latent TB may be eligible based on the investigator's benefit-risk assessment.
Patients with multiple lesions will be eligible as long as there are no overlapping fields of radiation, including at various time frames
In cases of lymphoproliferative disease arising in patients who are pharmacologically immunosuppressed, reduction of immunosuppression (RI) must be attempted prior to or in conjunction with enrollment, with the exception of those for whom RI would pose excessive threat of clinically significant graft rejection (as judged by local investigator)\r\n* NOTE: Patients who are otherwise immunosuppressed (for reasons such as immune dysregulation related to autoimmune conditions, in the absence of pharmacological immunosuppression) may be eligible if, in the opinion of the treating investigator, the risk of immediate treatment with rituximab-cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) outweighs the benefit for these patients
Patients who have had prior surgical intervention for lymphoma, unless performed for the sake of tissue diagnosis or on an urgent basis for disease-related threat to life, limb, or organ function, are not eligible
Patients who have received prior treatment with oral or intravenous fenretinide as a single agent are eligible, provided they did not experience severe toxicity related to fenretinide
Patients who have received prior treatment with oral or intravenous fenretinide as a single agent are eligible, provided they did not experience severe toxicity related to fenretinide
Other \r\n* Lung cancer with pleural effusion (wet IIIB) are not eligible \r\n* Recurrent cancers are not eligible \r\n* Diffuse metastatic spread confined to one organ system is ineligible; examples of this include leptomeningeal spread in the CNS and peritoneal carcinomatosis
Evidence of an active lesion including: plexiform neurofibroma, malignant peripheral nerve sheath tumor, or other cancer requiring concurrent treatment with chemotherapy or radiation therapy; patients not requiring treatment for these lesions are eligible for this protocol
Patients with fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold-active azoles for greater than  month will not be eligible for this protocol
Pediatric patients with radiographically recurrent or radiographically progressive non-hematologic malignancies (central nervous system [CNS] or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible
Patients with the following pure histologies of endometrial or ovarian cancer are not eligible for enrollment: germ cell, sex cord stroma, carcinosarcoma, or sarcoma.
Patients with tumor tissue uptake during NETSPOT PET that is equal to or higher than that in normal hepatic tissue (grade >= ) will be eligible; at the discretion of the principal investigator, patients with SCLC whose tumors have lower levels of uptake than liver during NETSPOT PET may be eligible for the study
Patients must have a pathologically confirmed adenocarcinoma of the biliary tract (intra-hepatic, extra-hepatic [hilar, distal] or gall bladder) that is not eligible for curative resection, transplantation, or ablative therapies
Patients with active bacterial infections with systemic manifestations (malaise, fever, leukocytosis) are not eligible until completion of appropriate therapy. Patients taking low-dose antibiotics for biliary obstruction are exempted from this exclusion criterion.
A prior or concurrent metastatic second malignancy within  years, even if it does not require active therapy; for example, patients with concomitant indolent B-cell malignancies will not be eligible; patients with a prior resected in-situ or stage I malignancy felt to be cured will be eligible
Clinical American Joint Committee on Cancer (AJCC) (AJCC, th ed.) II, IIIA or IIIB (with non-operable disease; non-operable disease will be determined by a multi-disciplinary treatment team within  days prior to registration; note: for patients who are clearly nonresectable, the case can be determined by the treating radiation oncologist and/or a medical oncologist or pulmonologist \r\n* Patients who present with N or N disease and an undetectable NSCLC primary tumor are eligible\r\n* Patients who refuse surgery are eligible\r\n* Patients who develop local recurrence after surgery and rendered candidate for definitive concurrent chemoradiation are also eligible\r\n* Patients who have received systemic treatment (up to  cycles of induction chemotherapy, or up to  months of targeted therapy) are eligible
Patients with active lesions suspicious for keratoacanthomas/cutaneous squamous cell carcinoma (cSCC); patients who have excision of keratocanthomas/cSCC, with dermatologic confirmation of the absence of active disease may become eligible
Patients must be accessible for treatment and follow up. Patients registered on this trial must receive protocol treatment and be followed at the participating center. This implies there must be reasonable geographical limits placed on patients being considered for this trial. Investigators must ensure that the patients randomized on this trial will be available for complete documentation of the treatment, response assessment, adverse events, and follow-up.
INCLUSION - PROCUREMENT: Any patient, regardless of age or sex, with measurable EBV-positive Hodgkins or non-Hodgkins lymphoma, (regardless of the histological subtype) or EBV (associated)-T/natural killer (NK)- or B cell lymphoproliferative disease\r\n* The first  patients enrolled will be adults; patients < years of age are eligible if those first  patients do not experience dose limiting toxicity considered to be primarily related to the EBVST or nivolumab\r\n* Patients with relapsed or refractory lymphoma who failed or are ineligible for an autologous hematopoietic cell transplantation are also eligible for this study
Patients must have received all approved therapies known to provide clinical benefit for their disease subtype and for which they are eligible or must have refused these treatment options prior to consideration for enrolment. In the case of patients who have lymphomas for which high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT) is considered a standard curative therapy, eligibility for this study requires that the patient's disease has relapsed after HD-ASCT, that the patient is not eligible for HD-ASCT, or that the patient has refused HD-ASCT.
Follicular grades IIIA or IIIB are not eligible
Patients previously treated with anti-CD CAR or other adoptive cell therapies will be eligible if all other eligibility criteria are met but will be evaluated as a separate strata from CAR-naive patients in the expansion phase; circulating CAR T cells must be < % in peripheral blood
Multifocal gliomas that are bilateral; patients with unilateral multifocal gliomas may be eligible if their multifocal disease can be treated effectively and safely in a single MLA procedure; also note that corpus callosal tumors are eligible even if they are bilateral as long as they satisfy the size and shape limits of MLA as determined by the performing neurosurgeon
Patients with mature B-cell ALL will be removed from the protocol as soon as that diagnosis is made and should be treated on a B-cell leukemia (Burkitts) protocol; NOTE: patients with T-cell surface markers and a t(;)(q;q) remain eligible
PHASE I: Patients with central nervous system (CNS) involvement are eligible provided that they are asymptomatic and in the opinion of the study principal investigator (PI) have a reasonable expectation that disease burden can be controlled in the interval between enrollment and T cell infusion; patients that have a significant neurologic deterioration will be not be eligible for T cell infusion until alternate therapies result in neurological stabilization
PHASE II: Patients with CNS involvement are eligible provided that they are asymptomatic and in the opinion of the study PI have a reasonable expectation that disease burden can be controlled in the interval between enrollment and T cell infusion; patients that have a significant neurologic deterioration will be not be eligible for T cell infusion until alternate therapies result in neurological stabilization AND
No prior genetically modified cell therapy that is still detectable or virotherapy allowed; patients who are otherwise eligible but have detectable circulating CAR T cells of < % will be eligible, but will be evaluated as a separate strata from CAR-naive patients in the phase  portion of the study
In Part  and, Part , subjects must have AML, MM, or NHL. Subjects with AML, are eligible if they  have relapsed and/or refractory disease, OR are>= years of age and not candidates for or have refused standard chemotherapy. Subjects with multiple myeloma are eligible if they have progressed despite therapy with an alkylating agent, proteasome inhibitor, and immunomodulatory agent, either as individual regimens or in combination. Subjects with NHL are eligible if they have received at least two prior lines of systemic therapy, including at least one line of immunochemotherapy with an anti-CD antibody (if their tumor expresses CD). In Part , the NHL cohort will separately enrol subjects with double- and triple hit lymphoma, so that a minimum of  subjects with this subset of disease will be enrolled. To be eligible for this sub-cohort, tumor sample from the subject must demonstrate rearrangement and/or overexpression of MYC and either BCL and/or BCL genes. Evaluation of double- or triple-hit status may be performed via appropriate local testing, and the determination of double- or triple-hit diagnosis will be at the discretion of the investigator and GSK Medical Monitor.
Patients requiring emergency radiation therapy are eligible for enrollment on this trial
Patients tumors will need to tested for the RAS mutation status; only those patients with wild-type or unmutated RAS oncogene are eligible to participate in this study
Patients who have been treated with prior secondary hormonal manipulations with proposed investigational rationale for having efficacy against AR-V splice variants. This includes but is not limited to EPI- and AZD. (Note: patients previously treated with abiraterone, orteronel [TAK-], apalutamide [ARN-], galeterone, or VT- will be eligible for this study. Patients who have received prior chemotherapy will also be eligible for this study).
Patients who have previously received bortezomib or other proteasome inhibitors that did not have a response while receiving the inhibitor are not eligible; patients that responded but had a subsequent relapse are eligible
Patients who have had less than or equal to  metastases treated with SRS are eligible.
Patients who are eligible for and willing to receive treatment with blinatumomab, inotuzumab ozogamizin, or tisagenlecleucel
All stages of disease (IA through IVB) where radiation therapy is being considered for local control are eligible. Patients who are concomitantly undergoing systemic therapy for more advanced stage disease are eligible.
Patients with a history of allergy to medications that have a benzamide structure (e.g., metoclopramide, procarbazine, domperidone, cisapride etc.) are not eligible
Inclusion Criteria:\n\n        Patients fulfilling the following criteria will be eligible to provide continued long-term\n        follow-up data as part of this study:\n\n          . Enrolled and randomized on the BMT CTN  protocol.\n\n          . Alive at the completion of BMT CTN  protocol specified follow-up defined as \n             years post-randomization.\n\n          . Patients without evidence of disease progression at the completion of BMT CTN \n             protocol specified follow up.\n\n          . Signed Informed Consent Form.\n\n          . Patients with the ability to speak English or Spanish are eligible to participate in\n             the HQL component of this trial.\n\n        Inclusion Criteria for Optional Long-term Lenalidomide Maintenance Therapy:\n\n        Patients fulfilling the following criteria will be eligible to provide continued long-term\n        follow-up data AND receive long-term lenalidomide maintenance therapy as part of this\n        study:\n\n          . Enrolled and randomized to BMT CTN .\n\n          . Completion of  years of maintenance therapy on BMT CTN .\n\n          . Registered in the mandatory Revlimid REMS program (formerly the RevAssist for Study\n             Participants (RASP) program), and be willing and able to comply with the requirements\n             of the Revlimid REMS program, including counseling, pregnancy testing, and phone\n             surveys.\n\n          . Signed informed consent form.\n\n          . Patients with the ability to speak English or Spanish are eligible to participate in\n             the HQL component of this trial.\n\n        Exclusion Criteria:\n\n        Patients who meet any of the following criteria will be ineligible to receive long-term\n        lenalidomide maintenance therapy as part of this study:\n\n          . Patients who have evidence of disease progression prior to enrollment.\n\n          . Patients who were discontinued from BMT CTN  lenalidomide maintenance therapy, for\n             any reason, prior to the completion of the  years of  maintenance.\n\n          . Female patients who are pregnant (positive - Beta Human Chorionic Gonadotropin) or\n             breastfeeding.\n\n          . Females of childbearing potential (FCBP) or men who have sexual contact with FCBP\n             unwilling to use contraceptive techniques during the length of lenalidomide\n             maintenance therapy.\n\n          . Patients who experienced thromboembolic events while on full anticoagulation during\n             prior therapy with lenalidomide.\n\n          . Patients unwilling to take Deep Vein Thrombosis (DVT) prophylaxis.\n\n          . Patients who developed a second primary malignancy, excluding non-melanoma skin\n             cancers after initiation of lenalidomide maintenance therapy on BMT CTN .
Patients who discontinued prior trastuzumab or T-DM due to progressive or refractory disease are eligible for enrollment; patients who discontinued prior trastuzumab or T-DM due to intolerance however are not eligible for enrollment
Subjects with central nervous system (CNS) involvement are eligible provided that they are asymptomatic and in the opinion of the study principal investigator (PI) have a reasonable expectation that disease burden can be controlled in the interval between enrollment and T cell infusion; subjects that have a significant neurologic deterioration will be not be eligible for T cell infusion until alternate therapies result in neurological stabilization
Diagnosis\r\n* Patients with CNS disease\r\n* Patients with isolated extra-medullary relapse involving only sanctuary sites (eg. testicular relapse) but patients with extramedullary disease involving nodal or other non-sanctuary sites are eligible\r\n* Patients with isolated testicular relapse \r\n* Patients with Philadelphia chromosome positive (Ph+) T-ALL/T-LLy\r\n* Patients with Down syndrome \r\n* Patients with pre-existing grade  (or higher) peripheral motor or sensory neurotoxicity per CTCAE . \r\n* Patients with a history of prior veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) or findings consistent with a diagnosis of VOD/SOS, defined as: conjugated serum bilirubin > . mg/dL AND unexplained weight gain greater than % of baseline weight or ascites AND hepatomegaly or right upper quadrant pain without another explanation, OR reversal of portal vein flow on ultrasound, OR pathological confirmation of VOD on liver biopsy
Patients with history of RAS mutation-positive tumors are not eligible regardless of interval from the current study. Prospective RAS testing is not required. However, if the results of previous RAS testing are known, they must be used in assessing eligibility.
Persons who are incarcerated or otherwise under compulsory detention by an authority are not eligible
Patients with DLBCL who best fit the criteria of EBV+ DLBCL, NOS are not eligible
Subjects with central nervous system (CNS) involvement are eligible provided that they are asymptomatic and in the opinion of the study principal investigator (PI) have a reasonable expectation that disease burden can be controlled in the interval between enrollment and T cell infusion; subjects that have a significant neurologic deterioration will be not be eligible for T cell infusion until alternate therapies result in neurological stabilization
Both metastatic and inoperable primary-only patients are eligible
Patients with extrahepatic disease are eligible
Patients with evidence of large B cell transformation (transformed disease) are not eligible; if in the opinion of the investigator there is high suspicion of transformed disease based on imaging (eg high standardized uptake value [SUV] uptake >  on the PET scan) and a biopsy of the suspected site is not feasible, then those patients are not eligible
Have recurrent or refractory/unresectable disease for which there is no known curative therapy\r\n* Wild type-GIST: patients with recurrent or progressive disease will be eligible; newly diagnosed patients with resectable localized disease will not be eligible; newly diagnosed patients with metastatic disease and newly diagnosed patients with residual tumor following surgical debulking will be eligible\r\n* PHEO/PGL: patients with recurrent or progressive disease will be eligible; newly diagnosed patients with PHEO/PGL that is metastatic at diagnosis and/or unresectable will be eligible; patients with PHEO/PGL with localized (non-metastatic), resectable disease will not be eligible\r\n* Renal cell cancer associated with HLRCC: patients with localized, resectable HLRCC-associated renal cell cancer will not be eligible; patients with metastatic and/or unresectable HLRCC-associated renal cell cancer will be eligible
Patients must be eligible to undergo high dose chemotherapy (HDT) followed by ASCT as a form of remission consolidation
Patients may have received any prior therapy deemed necessary for them to be eligible to HDT/ASCT except for patients whom have progressed while on Zydelig. Patients who have responded to Zydelig previously are eligible for enrollment on the protocol
Patients with known history of serous retinopathy will not be eligible
Patients will not be eligible if they have a history of color vision defects
Eligible for any higher priority transplant protocols
Patients who have undergone a diverting tracheostomy which is either a) traversing directly through tumor, b) has been placed for true airway insufficiency. Patients with a tracheostomy placed preemptively for impending airway compromise remain eligible for enrollment.
Female patients who are pregnant or lactating are not eligible (because treatment involves unforeseeable risks to the embryo or fetus)
Patients for whom SABR plans cannot meet the minimum requirement of target coverage and dose-volume constraints of critical structures (see SABR treatment planning section) are not eligible
Patients with evidence of another malignancy or benign tumor requiring chemotherapy or radiation therapy are excluded; however, those patients with a plexiform neurofibroma requiring treatment will be eligible as selumetinib has documented activity in plexiform neurofibromas
Patients with bulky disease are eligible for study provided that the patient not undergo radiation therapy until  days after the end of blinatumomab administration
Patients may have received chemotherapy or radiation for a previous, curatively treated malignancy provided at least  years have elapsed and there is no current evidence of disease (patients with previous or concurrent additional skin cancers will be eligible); patients with chronic lymphoid or leukemic malignancies are eligible with or without active disease as long as they have not had treatment within the past three months
Patients should not be eligible for potentially curative surgical intervention in the case of oligometastatic disease at the time of enrollment or must have actively refused after explicit discussion of potential benefit of this intervention with multidisciplinary team
Per investigator's judgment, be eligible for treatment with valganciclovir.
Patients must have failed a prior >= -mponth course of either MMF/Myfortic or cyclophosphamide before being eligible for the study (determined at >=  week before start of mobilization); failure is defined as evidence of disease progression or absence of improvement; the response prior to MMF of cyclophosphamide will be assessed by the participating site study rheumatologist
Patients with prior selective internal radiation are candidates are eligible as long as they are candidates for repeat procedures and they have demonstrated progressive disease.
Eligible for LDAC therapy, based on Investigator assessment
MPNST for which standard therapy is not curative, including patients with surgically unresectable lesions, progression (WHO criteria) or recurrence of an MPNST in a previously radiated field (if it has been at least  weeks prior to registration since the last dose of radiation); Note: patients with metastatic disease also are eligible for participation
Patients with clonal evolution and no other criteria for accelerated phase will be eligible for this study
Patients with cytopenias below these thresholds deemed to be the result of disease will be considered eligible
Patients on EIADs are not eligible, unless the antiepileptic drug can be safely tapered and discontinued before CD.
For Part  and Part  of the study, participants that are eligible to undergo first time HD-ASCT.
Patients must be eligible for TACE
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Have a surgically resected (R or R) American Joint Committee on Cancer (AJCC) pathologic stage I or stage II adenocarcinoma of the head, neck, or uncinate of the pancreas; (following study treatment #, if the patients tumor is found intraoperatively to be limited to the distal portion (body or tail) of the pancreas and is resected by distal pancreatectomy, the patient may continue to receive study treatments but will be considered non-evaluable for the primary and efficacy endpoints and will be followed for additional endpoints;) the patients with an R resection will not be eligible for the continuation of the study; patients with intraoperative findings of metastatic disease will not be eligible for the continuation of the study
Patients with newly diagnosed or progressive DIPG as confirmed by gadolinium enhanced magnetic resonance imaging (MRI) are eligible; MRI must demonstrate that at least / of the tumor is situated in the pons and that the origin of the tumor is clearly in the pons; biopsy is not required; tumors with features not typical of diffuse intrinsic brainstem glioma are not eligible; these include dorsally exophytic brainstem gliomas, cervicomedullary junction tumors, and focal low grade gliomas of the midbrain or brainstem which should undergo resection and pathologic evaluation; patients, who have received re-irradiation for progression of the tumor, will be eligible if they show evidence of measurable progressive disease after the re-irradiation; patients at diagnosis with involvement of the spine will not be eligible, however if at progression features of spine involvement are present they will be eligible for stratum II
At least  weeks should have elapsed since the last dose of chemotherapy and must have recovered from the acute effects of prior therapy (grade  or better); however patients who have a > % rise in peripheral blast count (confirmed twice) or > % growth of lymph nodes are immediately eligible; patients who have relapsed following autologous or allogeneic bone marrow transplant (BMT) are eligible
Patients with neurofibromatosis are eligible
Patients eligible for this study should have locally and/or regionally advanced melanoma that is considered potentially surgically resectable and with biopsiable tumor at baseline
Uncontrolled infections; patients still under therapy for presumed or proven infection are eligible provided there is clear evidence (radiologic, clinical and/or culture) that the infection is well controlled
For patients undergoing SABR, both early stage primary lung cancer patients and those with limited metastatic disease to the lungs are eligible; however, patients with oligometastatic disease should have a controlled primary and no more than one other involved organ system
Patients with multiple viral infections including AdV are eligible if their AdV infection is persistent despite standard therapy as defined above. Patients with multiple infections with one or more reactivation and one or more controlled infection are eligible to enroll.
Patients must have high-risk neuroblastoma as defined by the Children's Oncology Group (COG) Risk Stratification Schema\r\n* Patients with International Agreement on Staging (INSS) stage  are eligible with the following:\r\n** MYCN amplification, regardless of age or additional biologic features OR\r\n** Age >  months, regardless of biologic features OR\r\n** Age - months, with any of the  following unfavorable biologic OR features: MYCN amplification, unfavorable pathology, and/or deoxyribonucleic acid (DNA) index = \r\n* Patients with INSS stage  are eligible with the following:\r\n** MYCN amplification, regardless of age or additional biologic features OR\r\n** Age >  months with unfavorable pathology, regardless of MYCN status\r\n* Patients with INSS stage a or b are eligible with the following:\r\n** MYCN amplification, regardless of age or additional biologic features\r\n* Patients with INSS stage s are eligible with the following:\r\n** MYCN amplification, regardless of additional biologic features
Patients with multiple CMV, EBV, adenovirus, HHV and BK virus infections are eligible given that each infection is persistent despite standard therapy; patients with multiple infections with one or more reactivation and one or more controlled infection are eligible to enroll
Only patients with mutated rat sarcoma (RAS) (KRAS and NRAS) mutations are eligible to participate (Phase II only)
Inclusion Criteria\n\n        -Male or female patients ? years of age who present with one of the following:\n\n        LGH monotherapy arm\n\n          -  Refractory/Relapsed AML following no more than  prior therapies, or in previously\n             untreated AML patients who are not candidates for standard therapy.\n\n          -  High and very high risk MDS according to the revised International Prognostic Scoring\n             System (rIPSS) who have failed prior therapies, such as azacitidine and decitabine\n\n          -  Patients with rIPSS score of > .\n\n        LGH and midostaurin combination arm\n\n          -  Refractory/Relapsed AML following no more than  prior therapies, or in previously\n             untreated AML patients who are not candidates for standard therapy. AML patients may\n             have either FLT wild type or FLT-ITD/TKD mutant disease, and FLT mutation status\n             needs to be defined at study entry.\n\n               -  For AML patients, peripheral blast counts < , blasts/mm\n\n               -  For MDS patients;\n\n          -  Platelet count > ,/mm\n\n          -  Neutrophils > /mm\n\n          -  Blood transfusions are allowed to maintain clinically adequate hemoglobin and\n             hematocrit levels\n\n               -  Patients with active central nervous system (CNS) disease are eligible to\n                  participate and may be treated concurrently with intrathecal (or intra Ommaya)\n                  chemotherapy\n\n               -  Patients who are maintained on prophylactic antibiotics are eligible to\n                  participate as long as agents comply with the list of approved concomitant\n                  medications\n\n               -  Performance status ? \n\n               -  Meet other lab criteria\n\n        Exclusion Criteria\n\n          -  Systemic antineoplastic therapy (including unconjugated therapeutic antibodies and\n             toxin immunoconjugates) or any experimental therapy within  days or  half-lives,\n             whichever is longer, before the first dose of LGH monotherapy or LGH in\n             combination with midostaurin\n\n          -  Radiotherapy with a wide field of radiation within  days or radiotherapy with a\n             limited field of radiation for palliation within  days of the first dose of LGH\n             monotherapy or LGH in combination with midostaurin\n\n          -  Patients who received CNS irradiation for meningeal leukemia, except if radiotherapy\n             occurred >  months previously\n\n          -  Major surgery within  weeks before the first dose of LGH monotherapy or LGH in\n             combination with midostaurin\n\n          -  Ongoing therapy with corticosteroids greater than  mg of prednisone or its\n             equivalent per day. Inhaled and topical steroids are permitted\n\n          -  Patients who are currently receiving hydroxyurea to control peripheral blood leukemic\n             blasts and cannot be discontinued for at least  hours prior to obtaining PD\n             biomarkers at screening/baseline and during the study\n\n          -  Patients who are currently receiving treatment with prohibited medication and that\n             cannot be discontinued at least one week prior to the start of treatment with LGH\n             monotherapy or LGH in combination with midostaurin\n\n          -  Active infection requiring systemic therapy or other severe infection, including\n             pneumonia, within  weeks before the first dose of LGH monotherapy or LGH in\n             combination with midostaurin\n\n          -  Known human immunodeficiency virus (HIV) positive\n\n          -  Corrected QT interval (QTc) of >  milliseconds (ms) in males and >  milliseconds\n             (ms) in females on baseline electrocardiogram (ECG) (using corrected QT interval using\n             Fridericia [QTcF] or local standards).\n\n          -  Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias,\n             congestive heart failure, angina, or myocardial infarction within the past  months\n\n          -  Pregnant or nursing
An international normalized ratio (INR) =< . (patients who are therapeutically anticoagulated for unrelated medical conditions such as atrial fibrillation and whose antithrombotic treatment can be withheld for operation will be eligible)
Patients who have met the above criteria and who have undergone CRS and HIPEC in the past  months for the forementioned disease processes without evidence of recurrence will be eligible for participation in this study for analyzing ability to achieve complete cytoreduction, morbidity, progression and survival
F. Any one of the below complications\r\n* Vaso-occlusive crises; eligible for hydroxyurea*: at least  hospital admissions in the last year; eligible for hematopoietic stem cell transplantation (HSCT): more than  hospital admission per year while on maximal tolerated dose of hydroxyurea*\r\n* Acute chest syndrome (ACS); eligible for hydroxyurea*:  prior ACS while >  years of age and adequately treated for asthma; eligible for HSCT: any ACS while on hydroxyurea*\r\n* Osteonecrosis of  or more joints; eligible for hydroxyurea*: and significantly affecting their quality of life by Karnofsky score -; eligible for HSCT: and on hydroxyurea* where total hemoglobin increase less than  g/dL or fetal hemoglobin increases < . times the baseline level\r\n* Red cell alloimmunization; eligible for hydroxyurea*: transfusion-dependent; eligible for HSCT: total hemoglobin increase <  g/dL while on hydroxyurea*\r\n* Note: hydroxyurea at maximum tolerated dose
Although rare, the only exception to this would be patients with Hashimotos thyroiditis who ARE eligible for participation
Patient must be eligible for SABR to one or more extra cranial sites
Patients who have had a positive SLNB but decline completion ALND are not eligible
Previous therapy:\r\n* It is expected that patients will have received upfront standard of care therapy for their respected disease\r\n* Patients who relapse after either single or tandem autologous BMT are eligible (>  months must have elapsed from start of last BMT)\r\n* Patients must be recovered from the acute toxicities of any prior chemo/radio/immunotherapy or BMT
Patients must be between  to  days after ASCT
Patients in whom therapy for APL was initiated on an emergent basis are eligible (patients may have already started treatment with ATRA, ATO, and/or one dose of idarubicin due to the urgency to start therapy early)
Patients who require or likely to require corticosteroids or other immunosuppressives for intercurrent disease are NOT eligible
Patients with refractory-relapsed ALL of any age are eligible, provided they are not eligible for regimens of higher priority
Men are not eligible for this study
Patients with instability of the spine requiring instrumentation as judged by a neurosurgeon are not eligible
Patients with cytogenetic abnormalities suggesting an improved prognosis [t(:), t(;) and inv()] will be eligible for transplantation in first remission
Patients can also be deemed not eligible for transplant because of specific organ toxicity; specifically, patients with pre-existing compromise to the heart, lungs, kidney, central nervous system (CNS) or liver may be excluded
Previous Therapies\r\n* Patients who are currently being treated with intrathecal (IT) IL- for LMD are eligible; no wash out period is required\r\n* Patients who have been previously treated with other IT therapies are eligible, as long as there is at least a  week wash out period\r\n* Patients who have previously received therapy with systemic TIL therapy are eligible\r\n* Patients with ventriculo-peritoneal (VP) shunts must have VP shunts with on/off valves and must be expected to tolerate VP shunt valve off for more than  hours; patients who have received CNS irradiation, including whole brain radiation or stereotactic radiosurgery, are eligible, if they are at least  weeks post CNS-irradiation (Cohort D); patients who are currently being treated with IT IL- for LMD are eligible; no wash out period is required. (Cohort D)
Clinically stable and eligible to receive conditioning chemotherapy
FGFR testing of patients will be performed at the investigators' discretion up to a max. of  days prior to start of screening. Investigators should ensure all patients will be eligible in terms of disease status and lines of treatment within this timeframe.
Patients are eligible unless their treatment is to be guided by a higher priority protocol
Patients with myelodysplastic syndrome, aplastic anemia or hemoglobinopathies will be eligible to participate regardless of disease status if plan is to proceed to HCT
Prior history of standard dose focal RT to  Gy in  fractions or . Gy in . Gy fractions, or equivalent or lower doses; patients who have received prior treatment with non-standard RT dose and fractionation schemes are still eligible, provided they have only received a single course of RT; however, subjects treated with interstitial brachytherapy or single-fraction stereotactic radiosurgery are not eligible for this trial
Complex stenoses (Bismuth grade IV) will not be eligible for the trial
Patients with rectal disease
Patients are eligible if they are going to receive TMZ as part of the standard adjuvant treatment regimen following concomitant TMZ/radiation therapy (RT)
Patients are not eligible who have had major surgery =<  days of registration; please contact principle investigator (PI) and quality assurance monitor (QAM) for questions about specific surgical procedures
Patients must have had at least one episode of disease recurrence in the lungs without limitation on number of episodes of recurrence as long as they meet the following criteria:\r\n* Surgical resection of all possible sites of suspected pulmonary metastases in order to achieve a complete remission within  weeks prior to study enrollment**\r\n* Pathologic confirmation of metastases from at least one of the resected sites\r\n** For patients with bilateral pulmonary metastases, resection must be performed from both lungs and the study enrollment must be within  weeks from date of the last lung surgery\r\n* Note: If surgery related changes such as atelectasis are seen on the post-operative computed tomography (CT) scan, patients will remain eligible to enroll as long as the operating surgeon believes that all sites of metastases were resected; patients with positive microscopic margins will be eligible to enroll
Patients with feeding tubes are eligible for the study
Patients with hypothyroidism that is clinically stable and have normal TSH levels with hormone replacement, or patients with vitiligo or psoriasis not requiring treatment remain eligible for the study
Patients with feeding tubes are eligible for the study
Patients with known human immunodeficiency virus (HIV) infection are eligible if being treated with non-interacting antiretroviral (ARV) agents or be willing to stop ARV for the protocol
Subjects with FAB M (t(;)(q;q)[PML-RARalpha]) are not eligible
Patients with history of rat sarcoma (RAS) mutation-positive tumors are not eligible regardless of interval from the current study; Note: RAS testing and absence of RAS mutation are required for eligibility
Patients must have stable disease at the time of enrollment
Participants who have received any chemotherapy or radiotherapy for previous malignancy are not eligible; participants who have ever previously received any anti-neoplastic agent, including methotrexate, -mercaptopurine, -thioguanine, vincristine cyclophosphamide, cytarabine (except for IT cytarabine), or any anthracycline, for any reason (e.g., rheumatologic or autoimmune condition) are not eligible
Newly diagnosed, previously untreated: () M medulloblastoma with > . cm^ residual; () M+ medulloblastoma; patients with diffusely anaplastic medulloblastoma are eligible regardless of M-stage or residual tumor\r\n* As of amendment # , enrollment of patients with supratentorial PNET has been discontinued\r\n* All patients with M disease are not eligible
Patients with a paraben allergy cannot take isotretinoin preparations containing this compound (i.e. Accutane, Sotret) but are eligible if they can take an alternate preparation without paraben; (applicable only for entry onto dose levels receiving isotretinoin)
Patients with intracranial metastases, which have been treated by surgery or radiation therapy, may be eligible for study provided there is no evidence of active disease and no requirement for anticonvulsant therapy or steroids following treatment
Patients with unknown primary melanoma (Tx) who present with cutaneous, subcutaneous, nodal and/or lung metastases that are completely surgically resected with free margins are allowed; these patients are allowed even if they dont fit the strict staging criteria; for stage IV patients LDH within the institutional ULN must be documented within  weeks prior to randomization (Mc is not eligible) \r\n* NOTE: all subjects should be classified as IIIB, IIIC, Ma or Mb including subjects with disease recurrence after adequate surgical excision of the original primary melanoma; that is the treating team/physician investigator should review an overall TNM status (that includes primary tumor presentation and disease recurrence status) and provide a designation of IIIB, IIIC, Ma or Mb
Patients whose tumors arise in the dural and intra-dural soft tissues of the cranium and spine are not eligible
Patients with anaplastic medulloblastoma are eligible regardless of M-stage or residual tumor
Patients requiring anticonvulsants known to activate the cytochrome p system, in particular anticonvulsants such as phenytoin, carbamazepine, and phenobarbital, are not eligible; benzodiazepines and gabapentin are acceptable
ALL patients who cannot receive any asparaginase products (E. Coli, PEG-asparaginase, or Erwinia asparaginase) on this study (eg, due to prior severe pancreatitis, stroke or other toxicity) are not eligible; patients with clinically significant prior allergies to PEG-asparaginase are eligible if Erwinia L-asparaginase can be substituted
Patients who have an uncontrolled infection are not eligible; infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines are acceptable
Extradural masses that have not invaded the brain parenchyma or parameningeal tumors without evidence for leptomeningeal spread will not render the patient ineligible; patients with previous central nervous system (CNS) tumor involvement that has been treated and is stable for at least  weeks following completion of therapy are eligible; patients who are clinically stable as evidenced by no requirements for corticosteroids, no evolving neurologic deficits and no progression of residual brain abnormalities without specific therapy, are eligible one week post radiation or radiosurgery; patients with asymptomatic sub-centemeric CNS lesions will be eligible if no immediate radiation or surgery indicated
Patients with a history of RAS mutation-positive tumors are not eligible regardless of interval from the current study; Note: prospective RAS testing is not required; however if the results of previous RAS testing are known, they must be used in assessing eligibility
Patients with history of rat sarcoma (RAS) mutation-positive tumors are not eligible regardless of interval from the current study; Note: prospective RAS testing is not required; however, if the results of previous RAS testing are known, they must be used in assessing eligibility
Patients must not be eligible for full ablative regimens by the attending physician
Patients receiving nilotinib  mg PO BID or a lower dose are not eligible
History of hemoptysis within  days of registration; Note: patients who have minimal bleeding from the mouth, which is clearly not related to a source in the lungs, i.e., surgery such as a non-lung biopsy, are eligible only after good hemostasis has been documented
Prior chemotherapy:\r\n* Ovarian cancer: patients with no prior PLD exposure are eligible after failure of platinum-containing chemotherapy; no more than  prior platinum containing regimens is permitted; dose escalating cohorts only: patients already on PLD are also eligible if they are receiving PLD beyond  cycles without prohibitive (i.e. no grade  or ) skin or mucosal toxicities, and showing no progressive disease compared to a computed tomography (CT) scan obtained  or more months earlier; these patients are eligible in spite of any progression from baseline determined prematurely (i.e., applicable to those patients who are deemed in their best interest to continue to receive PLD after a CT obtained at  or  months has shown progression from baseline)\r\n** Breast cancer: patients may have received - prior chemotherapy regimens for metastatic disease; breast cancer patients may not have received prior PLD, and will not be eligible for the expanded cohort A \r\n** Interval between prior chemotherapy and registration for breast and ovarian cancer; there should be at least a  week interval between the last chemotherapy regimen and registration, and the patient should have recovered from acute toxicity related to prior therapy ( weeks if the last regiment included BCNU or mitomycin C)\r\n** Dose escalating cohorts only: patients will be categorized in the following strata based upon prior PLD exposure: Stratum A patients with ovarian cancer who have had prior PLD exposure and received at least  cycles of PLD without prohibitive (i.e. no grade  or  skin toxicity) and have not had progressive disease; Stratum B: patients with ovarian or breast cancer who have had no prior PLD exposure
* Phase  (Part A) - COMPLETE: Patients with relapsed or refractory neuroblastoma, with or without bone marrow involvement, who are not eligible for Part A or A or cannot enroll on Part A because of stratum suspension or lack of available slots (these patients will be enrolled at one dose level below the dose level at which patients on Part A are actively enrolling)
Patients with fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold-active azoles for greater than  month will not be eligible for this protocol (either regimen A or B)
Patients eligible for any higher priority transplant protocols
This eligibility criterion does not apply to patients enrolled after August , ; patients who are not candidates for surgical cytoreduction are eligible for the chemotherapy randomization; patients are not considered candidates for surgical cytoreduction if complete cytoreduction in the estimation of the investigator is impossible or a medical infirmity precludes exploration and debulking
Tumor Requirements: All Patients must have at least one measurable target extracranial lesion according to RECIST v.. In addition patients with asymptomatic CNS metastases (including patients asymptomatic by means of stable or decreasing doses of steroids within the last  weeks prior to study entry) will be eligible. Patients who have leptomeningeal disease (LM) or carcinomatous meningitis (CM) are eligible.
Patients presenting with tumors within the kidneys (multiple synchronous or single/multiple metachronous) are not eligible if there are no extrarenal sites of disease (i.e. potential multifocal primary disease)
Eligible for and consenting to ASCT
Patients with - brain metastases, each <  cm by contrast MRI, with stable systemic disease and ECOG score of -, who would otherwise be eligible for SRS/stereotactic radiation therapy (SRT) alone should not be enrolled into this study unless WBRT is recommended due to any medical reasons or logistic limitations as determined by the treating physician; patients who develop recurrence post-SRS/SRT or surgery alone and are recommended WBRT will be eligible for the protocol
Previous treatment with investigational agents that inhibit MDM or MDMX activity (some MDM-treated patients may be eligible)
History of hypertriglyceridemia with triglyceride levels >  mg/dl; patients with triglyceride levels <  receiving treatment for hypertriglyceridemia or hyperlipidemia are considered eligible
Patients with high-risk uterine leiomyosarcoma (LMS), Federation of Gynecology and Obstetrics (FIGO) stage I (confined to corpus +/- cervix); patients with known uterine serosa involvement are not eligible; patients should have had, at least, a complete hysterectomy (including removal of the cervix); bilateral salpingo-oophorectomy is not required \r\n* Institutional pathology review calls the uterine leiomyosarcoma high grade\r\n* Additionally, if the pathology report indicates a mitotic rate, the mitotic rate should be greater than or equal to  mitoses/ high-power field\r\n* All patients must be no longer than  weeks ( months) from surgical resection of cancer at the time of enrollment on study; if a patient requires a second operation to complete her surgery, i.e., trachelectomy to remove the cervix and/or bilateral salpingo-oophorectomy (BSO), the  weeks may be counted from the time of the second operation\r\n* Patients who had a morcellation hysterectomy procedure that involved morcellation within the peritoneal cavity are eligible IF a second operation is performed and biopsies from the second procedure show no evidence of leiomyosarcoma
Eligible and able to secure sourcing for ibrutinib
MF PATIENTS: Patients must have an ECOG status -
Patients who have received any investigational products, antineoplastic therapies, or radiotherapy within  days prior to registration are not eligible; NOTE: patients actively receiving hydroxyurea are eligible and may continue to receive hydroxyurea through cycle  of protocol treatment; if the platelet count remains above  million after cycle , hydroxyurea can be used at the treating physicians discretion, if the platelets are  x ^/L, or more, or if there are symptoms from thrombocytosis
Paroxysmal nocturnal hemoglobinuria (PNH): Patients with the non-aplastic form of PNH (cellular bone marrow) who have had a history of life-threatening complications of their disease including thrombotic events, severe hemolysis or Budd Chiari syndrome are eligible; other patients may be considered following approval at PCC and approval by the Principal investigator
Patients with Gilbert's syndrome uncomplicated by other liver disease may be eligible if agreed upon by the investigator and medical monitor for the sponsor.
Patients who only present with localized disease
Patients not considered in the opinion of the investigator eligible, or patients unwilling to undergo intensive salvage therapy including ASCT
Subjects must not be eligible for therapy of higher curative potential where an alternative treatment has been shown to prolong survival in an analogous population.
Patients whose insurance will not cover proton therapy will still be eligible for the study
Patients with tumors adjacent to a vertebral body are eligible as long as all gross disease can be encompassed in the radiation boost field; the boost volume must be limited to < % of the ipsilateral lung volume
B-ALL patients must be enrolled on AALLB or APECB (if open for the classification of newly diagnosed ALL patients) prior to treatment and enrollment on AALL\r\n* Note: B-LLy patients are not eligible for AALLB, and can enroll directly onto AALL
Patients must have newly diagnosed National Cancer Institute (NCI) Standard Risk B-ALL or B-LLy Murphy stages I or II; patients with Down syndrome are also eligible\r\n* Note: for B-LLy patients with tissue available for flow cytometry, the criterion for diagnosis should be analogous to B-ALL; for tissue processed by other means (i.e. paraffin blocks), the methodology and criteria for immunophenotypic analysis to establish the diagnosis of B-LLy defined by the submitting institution will be accepted
B-ALL patients with testicular leukemia are not eligible for AALL
Eligible patients must have histopathologically confirmed myxoid liposarcoma with confirmation of DDIT rearrangement
Known KRAS or NRAS mutations:\r\n* All patients must have molecular testing performed in a clinical lab which includes codon  and  of KRAS; patients with any mutation in codon  and  of KRAS are not eligible for the protocol\r\n* Testing for additional codons in KRAS or testing for NRAS is not required; however, if such testing has been performed in a clinical lab and any mutation in codons  or  in KRAS, or codons , , , or  in NRAS is detected, the patient is not eligible for the protocol
Patients with T, NM disease are not eligible
Patients with ASM and MCL with or without an AHNMD are required to have at least one of the eligible organ damage findings as defined by the international consensus response criteria
Clinically significant autoimmune disorders or conditions of immunosuppression; patients with AIDS or HIV- associated complex or known to HIV antibody seropositive or known to be recently PCR+ for hepatitis B or C virus are not eligible for this study; virology testing will be done within  months of T cell infusion; the severely depressed or altered immune system found in these patients and the possibility of premature death would compromise study objectives
Patients with a significant intercurrent illness (any ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the detailed exclusion criteria and that is expected to interfere with the action of study agents or to significantly increase the severity of the toxicities experienced from study treatment are not eligible
Patients eligible, at the time of starting treatment, for curative therapeutic approaches (such as allogeneic transplant) are not eligible for the trial; however, patients who achieve CR or partial response (PR) as a result of therapy on this trial may proceed to allogeneic transplant
Subjects who desire to enroll in this study and for whom anti-HER- therapy is not available or contraindicated, may be eligible to enroll in this trial.
Patients (with skin metastases only) who will be therapeutically anticoagulated with heparins or Coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator); patients on aspirin and other platelet agents are eligible
Patients with a known or suspected urea cycle or other metabolic disorder are not eligible
Patients must be considered unresectable or inoperable. Patients with nodal recurrence after surgery for early-stage NSCLC are eligible if the following criteria are met:
Eligible patient must show evidence of wild-type (WT) p as assessed by central DNA sequencing conducted at Dr. Jeffrey Sklars laboratory at Yale University Cancer Center; note, that since patients with AML have a rapidly proliferating disease, patient can be enrolled and begin treatment prior to obtaining the results of this test; patients who are found to the TP mutated will be removed from study and can continue on single agent decitabine; however patients will continue to be followed for toxicity
Participants must be planning to receive or have received autologous stem cell transplantation; participants may enroll prior to ASCT, but will not be eligible to begin treatment until after ASCT, and must fulfill all inclusion and exclusion criteria at that time; ASCT will be performed according to institutional standards and is not a part of this study
Is not eligible or has refused any protocols of higher priority
Patients who have a known dasatinib-resistant ABL-kinase mutation such as TI are not eligible; for confirmation, please contact PI
Histologically confirmed de novo DLBCL by the th edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues published in ; patients with a history of indolent lymphoma excluded; patients with known primary mediastinal large B-cell lymphoma (PMLBCL) are excluded; patients with known c-v-myc avian myelocytomatosis viral oncogene homolog (c-myc) translocation (by fluorescence in situ hybridization) positive DLBCL are eligible for enrollment; c-myc testing prior to study enrollment is not required; availability of diagnostic biopsy samples in encouraged for the exploratory analysis but not required for enrollment; patients with \double-hit\ or \triple-hit\ lymphoma are eligible for enrollment
Patients of childbearing potential, not practicing adequate contraception, patients who are pregnant, or patients who are breastfeeding are not eligible for this trial.
Patients with chronic non-T-cell-based lymphocytic leukemia are eligible if they have isolated lymphocytosis (Rai stage O) on the condition that they do not require systemic treatment for their disease [\B\ symptoms, Richter's transformation, lymphocyte doubling time (< months) and they do not have lymphadenopathy of hepatosplenomegaly].
Patients who have undergone a diverting tracheostomy which is either a) traversing directly through tumor, b) has been placed for true airway insufficiency; patients with a tracheostomy placed preemptively for impending airway compromise remain eligible for enrollment
Patients who have received Gliadel wafers or alternating electrical field therapy are not eligible for this study
Histologic evidence of angiolymphatic invasion (ALI); Note: Cases termed focally suspicious for ALI but where no definitive ALI is found are eligible
Patients with radiation-associated gliomas will not be eligible
Patients with a history of non-central line related thrombosis, more than one prior central-line related thrombosis, or known coagulopathy will not be eligible; patients with a first degree family member with a known coagulopathy will be excluded, and therefore, obtaining a family history is essential when possible; patients actively on anticoagulation therapy are not eligible
Patients must not be eligible for a higher priority (e.g.; phase II/III), National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group, and Gynecologic Oncology Group (NRG) protocol for the same population if one exists
Significant dermatological disease including, but not limited to, skin drying and fissuring, paronychial inflammation, infectious sequelae (eg, blepharitis, cheilitis, cellulitis, cyst); exception: patients with grade =<  cetuximab-related rash, xerosis, fissures or paronychial inflammation are eligible
Participants who are receiving any other investigational agents\r\n* Patients who have previously received ibrutinib will be ineligible in the Phase Ib portion of the study of the CLL arm\r\n* MCL patients who have been on ibrutinib for less than  months ( days) from the time of registration are eligible in the Ib portion of the trial; no washout will be required
Eligible to receive treatment with the selected doublet-chemotherapy
Must be off prior systemic therapies for  weeks prior to enrollment; patients that have been previously treated with systemic therapy adjuvantly or for metastatic disease remain eligible as long as they continue to meet all other eligibility criteria (oligometastatic, no visceral metastasis >  cm, eligible for SABR)
Subjects of all genders and races are eligible
Patients with a history of intolerance to trastuzumab and/or adverse events related to trastuzumab that resulted in trastuzumab being permanently discontinued are not eligible for participation
Patients must have had at least one prior treatment for metastatic disease with standard chemotherapy and cetuximab in combination or as monotherapy. [Note: patients who received panitumumab instead of cetuximab are eligible.]
Patients must have CA level >=  to participate in the immunotherapy aspect of the trial and receive oregovomab; if the patient has CA >=  who is not eligible to receive oregovomab (e.g. allergic to the drug) but is eligible for the rest of treatment, this patient should be accrued to the part of protocol without oregovomab
Eligible for and planning to receive maintenance temozolomide after completion of definitive radiotherapy plus temozolomide
Patients who have received yttrium- microspheres are not eligible
Patients with NF (neurofibromatosis) are eligible, and may have other stable central nervous system (CNS) tumors, such as schwannoma, acoustic neuroma, or ependymoma, but ONLY if these lesions have been stable in size for the preceding  months
Patients with multifocal or multicentric disease are eligible as long as each tumor individually meets eligibility criteria; central confirmation is needed for any site of disease that is tested to be HER-positive by local testing (unless testing was done by Clarient)
Eligible for allogeneic transplant in the treating physicians judgment and by institutional standards
PARTS A AND B: Patients with Hodgkin lymphoma (HL) are eligible for both the phase  and  portions, if they are in one of the following categories:\r\n* Primary refractory disease (i.e. no prior CR) \r\n* Very early relapse (<  months from the end of initial therapy, including chemotherapy  radiation)\r\n* Advanced stage (III or IV) at diagnosis who relapse less than one year from the end of initial therapy\r\n* Note that patients with low-stage disease (IA or IIA) at initial diagnosis, who were treated with radiation alone or fewer than four cycles of chemotherapy will NOT be eligible
Disease confined to the intraperitoneal and retroperitoneal cavity; Note: nodal disease below the diaphragm, implants adherent to the surface of the liver or intrahepatic lesions will not be exclusionary; patients remain eligible if all intrahepatic tumor is debulked or ablated by the time treatment is initiated
Patients who have taken any benzimidazole (ABZ, flubendazole, thiabendazole, fenbendazole, triclabendazole, etc.) within the last  months
Patients with second malignancies in remission may be eligible if there is clinical evidence of disease stability for a period of greater than  months off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy, are eligible.
Criteria that need to be met to participate in this study:\n\n          -  Patients must be >  months and <  years of age when registered on study.\n\n          -  Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than\n             a partial response to standard treatment or persistent neuroblastoma that had at least\n             a partial response to standard treatment. All patients must have at least ONE site of\n             evaluable disease.\n\n             o Patients who have at least a partial response to standard treatment who still have\n             neuroblastoma that can be seen on CT/MRI or MIBG scans must have a surgical biopsy\n             done of the tumor to confirm that it is neuroblastoma. Patients with relapsed or\n             refractory neuroblastoma do not need to have a biopsy done to enter on study.\n\n          -  Patients must have adequate heart, kidney, liver and bone marrow function. Patients\n             who have bone marrow disease must still have adequate bone marrow function to enter\n             the study.\n\n          -  MLN must be swallowed as whole tablets. Therefore, patients must be able to\n             swallow pills to be eligible for study. One tablet is the size of small breath mint,\n             or baby aspirin. Due to the size of MLN tablets, patients must have a body surface\n             area of at least . m to be eligible for study. A body surface area is a\n             combination of a patient's height and weight. An example of a child with a BSA of .\n             is a child that is  inches tall and weighs  pounds.You can use the link below to\n             calculate your child's body surface area and determine if they are too small for this\n             trial.\n\n        Patients cannot participate in the study if:\n\n          -  Patients who have received prior MLN are excluded from all phases of the study.\n             Patients previously treated with irinotecan and/or temozolomide will be eligible if\n             they have not had documented progressive disease during treatment with a regimen\n             containing these agents.\n\n          -  They have other medical problems that could get much worse if they had this treatment.\n\n          -  They are on dialysis for bad kidney function.\n\n          -  They are pregnant or breast feeding.\n\n          -  They have active infections such as hepatitis or fungal infections.\n\n          -  They have an allergy to treatment with cefixime and cefpodixime.\n\n          -  They have brain metastasis at study entry, or have received cranial spinal radiation.\n\n          -  They have had an allogeneic stem cell transplant (received stem cell from someone\n             else).\n\n          -  They can't cooperate with the special precautions that are needed for this trial.
Patients must discontinue antiandrogen therapy for at least  weeks (e.g. flutamide, bicalutamide, nilutamide) prior to registration with no evidence of a falling PSA after washout; patients on steroids are eligible as long as they will be switched to prednisone
Patients with a history of thromboembolism unrelated to a central line, or patients with a known predisposition syndrome for thromboembolism are not eligible
Both KRAS wild type and KRAS mutant patients are eligible
Patients scheduled to undergo laparotomy *Both optimal and suboptimal patients will be eligible for the study (Suboptimal patients, as well as those who undergo only exploratory laparotomy, are eligible.)
Individuals who do not meet criteria for cohort  (progressive disease) or cohort  (eligible for surgery) are not eligible for enrollment (i.e. patients with previously untreated disease that is not amenable/planned for surgical resection are not eligible)
Presence of life-limiting extra-hepatic metastasis that requires a systemic treatment within  months; patients with extra-hepatic metastasis that can be controlled with a loco-regional treatment are eligible
Patients must not have any disease that will obscure toxicity or dangerously alter drug metabolism; patients with a history of psychosis/schizophrenia or cardiac disease requiring beta-blocker treatment (unable to change medication to non-beta blocker), anti-malarial drugs, or quinine or quinidine will not be eligible for enrollment to a mefloquine containing arm; patients who are on active treatment with one of the study drugs at the time of evaluation will not be eligible for enrollment to an arm containing that study drug
Patients with uncontrolled diabetes mellitus or a fasting plasma glucose > . ULN; note: optimal glycemic control should be achieved before starting trial therapy; at the principal investigators discretion, non-eligible patients can be re-screened after adequate medical therapy has been instituted
Patients consuming >=  servings per day of fruits and vegetables (not including juices), as determined by the run-in dietary recalls, are not eligible
Patients must have progressed after at least one prior systemic therapy for GCT and meet one of the following criteria:\r\n* Patients with evidence of progressive or recurrent GCT after progression prior high dose chemotherapy (HDCT) treatment, defined as meeting at least one of the following criteria:\r\n** Tumor biopsy of new or growing or unresectable lesions demonstrating viable GCT; in the event of an incomplete gross resection where viable GCT is found, patients will be considered eligible for this study\r\n** Consecutive elevated serum tumor markers (HCG or AFP) that are increasing; increase of an elevated lactate dehydrogenase (LDH) alone does not constitute progressive disease\r\n** Development of new or enlarging lesions in the setting of persistently elevated HCG or AFP, even if the HCG and AFP are not continuing to rise\r\n* Patients deemed not to be a candidate for or benefit from potentially curative HDCT or other curative treatment options defined as follows:\r\n** Patients with inadequate renal function for HDCT\r\n** Patients who have had  or more lines of prior chemotherapy\r\n** Patients with late relapse (relapse >  years after last therapy)\r\n** Patient with inadequate stem cell collection to move forward with HDCT\r\n** Patients with significant medical or psychosocial comorbidities that are felt to be a contraindication to HDCT by the treating investigator\r\n* NOTE: There is no maximum number of prior treatments allowed\r\n* NOTE: Patients with clinically growing \teratoma\ (normal declining tumor markers and radiographic or clinical progression) should be considered for surgery; in patients with rising tumor markers as their only evidence of disease progression where AFP is <  or HCG is < , alternate causes of increased levels of these markers should be ruled out; (e.g., hypogonadism by testosterone suppression of luteinizing hormone [LH], hepatitis, use of marijuana)
Patients with contralateral mediastinal disease (N) are eligible if all gross disease can be encompassed in the radiation boost field in accordance with the heterogeneity criteria; patients with superior sulcus tumors, or scalene, supraclavicular, or contralateral hilar node involvement, will be eligible if the RT treatment plan allows the dose to the critical structures to be within the tolerance limits (e.g. the dose per fraction can be changed to .Gy for the lymph nodes and  Gy per fraction for the primary tumor) while keeping total dose to  Gy
Women with non-invasive disease or microinvasion are not eligible
Patients with a creatinine greater than . times the upper limit of normal are eligible, but will be told that they are at greater risk for kidney damage that could possibly result in temporary or even permanent dialysis
Patients must not have: a) active infection; b) disease that will obscure toxicity or dangerously alter drug metabolism, especially liver disease; c) serious intercurrent medical illness; d) prior treatment with HDAC inhibitors. However, patients who have received anticancer agents for non-therapeutic purposes (for eg., as part of a pharmacology study without therapeutic intent) will remain eligible for enrollment into the study.
Both pediatric and adult patients of any age are eligible
Treatment with hydroxyurea, busulfan, cytoreductive agents other than frontline TKI, or an investigational agent within  days of registration; patients who are on alpha-interferon as primary therapy are not eligible
Patients with evidence of disease are only eligible if the disease is stable (or persistent) in comparison to the status prior to transplantation
Transplant eligible patients are eligible
Patient's ALT and AST must be <  x institutional upper limit of norm ULN. The hepatic requirements are waived for patients with known or suspected liver involvement who would otherwise be eligible after consultation with the Study Chair or Vice Chair.
Patients who cannot receive cyclophosphamide
Patients with cytogenetic breakpoint cluster region (BCR)-Abl variants and additional chromosomal abnormalities (clonal evolution) will be eligible; cytogenetics to be performed, but results are not required to start therapy in patients with hematologic progression
Patients must have potentially resectable non-small cell lung cancer (NSCLC) by VATS as determined by a multidisciplinary team review; this primary should not have undergone any neoadjuvant chemotherapy (chemo-) or radiation therapy; only those patients undergoing surgery by conventional VATS will be included; (robotic procedures will not be eligible for inclusion in this study)
Patients with known active brain metastases; patients with a history of treated brain metastasis are eligible if the patient is off systemic steroids and there are no clinical indications of central nervous system (CNS) progression for a least  month; patients with glioblastoma multiforme are eligible if the above criteria are otherwise met; note: many clinical trials do not allow enrollment of such patients; if the physician, in good conscience, feels that applicable protocols for their patient do exist, enrollment onto this trial is acceptable, assuming other eligibility criteria are met
Patients with any tumor (T) with node (N) or N are eligible; patients with T, N-N disease are eligible if deemed unresectable; patients with T, any N are eligible
SCREENING: Patients with clinically evident or histologically proven sarcomas, melanomas, germ cell tumors, or epithelial malignancies metastatic to the lungs, mediastinum, or pleura who can be rendered no evidence of active disease (NED) following standard surgical therapy; note: patients with active disease outside the thorax may be eligible for the study once the extrathoracic disease is definitively treated by local modalities such as radiation, surgery, or radiofrequency ablation
SCREENING: Patients with no more than  intracranial metastases, which have been definitively treated by surgery or radiation therapy may be eligible for study provided there is no evidence of active disease for at least  months
TREATMENT: Patients with no more than  intracranial metastases, which have been definitively treated by surgery or radiation therapy may be eligible for the study, provided there is no evidence of active disease for at least  months and no requirement for anticonvulsant therapy or steroids following treatment
History of (within  months prior to enrollment) of kidney, ureter, or bladder stones with clinically significant sequelae (e.g. (painless gross hematuria; pain with or without infection; hydronephrosis, etc); patients with otherwise stable non-occluding kidney stones regardless of stone type incidentally found in computed tomography (CT) scans are eligible; patients with prior history of uric acid stones are eligible regardless of time of onset
Minimal residual disease (MRD) will be defined separately for each test (fluorescence-activated cell sorting [FACS], FISH or cytogenetics) using standard accepted definitions (that may change over the course of this study and are therefore not listed); thus, patients will be considered eligible only in cases where residual leukemia (i.e., MRD) can be detected above control values; in cases where MRD testing is not conclusive or when there is no control value for the test, the attending pathologist will be engaged and patients will only be eligible in cases where there is clear evidence of MRD
Patients who are immunologically compromised (excluding corticosteroids used for control of tumoral edema) are not eligible
Having chronic hepatitis B or C will not exclude patients from participating if they are otherwise eligible; however, requiring treatment with interferon is an exclusion; patients must be stable without having received interferon in at least  weeks
Patients who have an active or uncontrolled infection are not eligible; patients on prolonged antifungal therapy are still eligible if they are culture and biopsy negative in suspected radiographic lesions and meet other organ function criteria
Patients with nodal disease are eligible
Patients must be eligible for Alliance A and must agree to proceed to enroll in A
Patients must be eligible to receive melphalan dose of  mg/m^
For dose expansion cohorts: Dose expansion portion of study will include two separate cohorts\r\n* One cohort will incorporate patients with esophageal, gastroesophageal junction (GEJ) or gastric carcinomas (squamous cell carcinoma or adenocarcinoma if predominant histology); these patients must have received at least one prior systemic therapy for metastatic disease; patients who had prior neoadjuvant or adjuvant chemotherapy as part of curative intent primary therapy but recurred in less than  months would also be eligible; patients with HER+ disease must have received trastuzumab with disease progression prior to enrollment; patients on this arm may have had prior treatment with drugs targeting the PD- pathway, but will be limited to a maximum of  patients\r\n* The second cohort will include patients who have progressed on prior PD- pathway inhibition (single agent or in combination) in solid tumor types where these drugs are standard of care; the reason for discontinuation of the prior PD- pathway drug must not have been for toxicity; eligible tumor types include melanoma, RCC, UC, NSCLC, and SCCHN, but subsequent tumor types wherein relevant agents become an approved standard of care would also become eligible
Newly diagnosed metastatic lung adenocarcinoma (recurrent or de novo) harboring sensitizing EGFR mutations (LR, exon  deletion, GA, LQ, SI, exon  insertions) with oligometastatic disease (=<  discrete lesions of disease irrespective of location, inclusive of the primary lesion):\r\n* All sites of disease must be amenable to definitive treatment with a local therapy (surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy) as determined by surgery, interventional radiology and radiation oncology\r\n* All intrathoracic lymph nodes (including hilar, mediastinal, and supraclavicular nodal disease) are considered  discrete lesion\r\n* Each brain metastasis is included as a distinct lesion\r\n* Patients already started on erlotinib are eligible as long as their sites of disease are determined to be eligible for definitive local therapy by consensus of the principal investigators within  weeks of the patient first taking erlotinib
Patients with second malignancies in remission may be eligible if there is clinical evidence of disease stability for a period of greater than  months off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy, are eligible.
Patients eligible for participation in Study CLTR- (Phase III study of CPX- NCT) or who have already participated in that study are not eligible for this study.
Patients must have received crizotinib monotherapy at  mg BID on a continuous dosing schedule for at least  days; patients must be planning to start treatment at least three days, but no more than  days after discontinuing crizotinib monotherapy; patients who were not able to tolerate  mg BID of crizotinib are not eligible for this study
Patients with multiple CMV, EBV or adenovirus infections are eligible given that each infection is persistent despite standard therapy as defined above; patients with multiple infections with one persistent infection and one controlled infection are eligible to enroll
Patients with cutaneous disease only are not eligible
Patients presenting with untreated cord compression, visceral metastases or those in need of immediate treatment are not eligible (patients with prior treatment and stability will be eligible)
? prior doses of fulvestrant are not eligible
Patients who are taking drugs which affect androgen metabolism (e.g. spironolactone, ketoconazole, finasteride, dutasteride) will not be eligible; patients who received any of these agents within the  months prior to evaluation will be reviewed for eligibility by the principal investigator on a case by case basis
Only patients with a test result, using the -gene Hh signature assay, indicating Hhpathway activated MB are eligible for this study. All available tumor material obtained at any time during the course of the patient's disease should be submitted for these analyses
Patients with prior allogeneic transplant are not eligible.Patients with a documented history of cerebrovascular accidents and/or TIA within the past  months are not eligible.
Patients who have recurrent hepatocellular carcinoma following hepatic transplantation are excluded unless the following criteria are met: i. Transplantation was performed at least  months prior to the relapse of HCC. ii. Patients are on stable immune suppressive therapy with no clinical evidence of rejection. iii. Are receiving ? . mg everolimus daily. d. Patients with known HIV infection are excluded. e. Patients with Hepatitis B are eligible provided there is no active viral replication. Patients with Hepatitis C who are not on interferon are eligible.
Patients who have a diagnosis of hepatocellular carcinoma made through radiologic imaging may be eligible, provided they meet the criteria according to the American Association for the Study of Liver Disease, AASLD (Bruix and Sherman, ; Bruix and Sherman, )
Have undergone surgical, medical and radiation oncology evaluations to confirm:\r\n* Eligible for infusional fluorouracil (-FU) or capecitabine\r\n* Will not undergo surgery for the study disease\r\n* Able to receive HDR brachytherapy
Patients treated by BCS or mastectomy and axillary dissection must have - positive axillary nodes (macrometastases, >  mm)\r\n* Note patients with additional nodal micrometastases (> .- mm) or isolated tumor cells (=< . mm) are eligible; patients with nodal disease limited only to micrometastases or isolated tumor cells are not eligible
Patients treated by mastectomy and SLNB alone must have only  positive axillary node (macrometastases, >  mm)\r\n* Note patients with additional nodal micrometastases (> .- mm) or isolated tumor cells (=< . mm) are eligible; patients with nodal disease limited only to micrometastases or isolated tumor cells are not eligible
Adult patients
Only patients who are expected to survive at least  weeks will be eligible for this study
Use of venous access devices made of materials other than silicone for the infusion of ganetespib; patients with these devices are eligible as long as the device is not used for the infusion
Eligible for ASCT
Patients must not have had disease progression while receiving siltuximab. For those patients originally assigned to placebo in the CNTOMCD study, patients who have received less than  months of siltuximab following crossover will also be eligible
Eligible diagnoses:
Patients who have a solitary bone metastasis that has been irradiated are not eligible.
Patients with a fasting plasma glucose > . ULN; Note: at the principle investigators discretion, non-eligible patients can be re-screened after adequate medical therapy has been instituted
Patients that are - months of age with INSS stage  and all  favorable biologic features (i.e., non-amplified MYCN, favorable pathology, and DNA index > ) are not eligible
Patients with current diagnosis of primary cutaneous ALCL (patients who have transformed to systemic ALCL are eligible).
Patient with suspected recurrence of osteosarcoma but who has not had surgery is eligible for enrollment but will not be randomized to receive study medication until deemed fully eligible following surgical removal of all lung nodules.
All patients must have CTCL diagnosed by morphologic, histochemical or cell surface marker criteria with stage never exceeding IB / IIB disease and mSWAT < %. CTCL patients with stage IA disease are not eligible for enrollment. CTCL patients with stage IB disease are eligible provided that they have failed a systemic treatment (this includes radiation). CTCL patients with bone marrow involvement but without lymph node involvement are eligible. Patients with a diagnosis of angioimmunoblastic T cell lymphoma are eligible, even with lymph node involvement. Age ?  years. Patients must have a performance status of <  on Eastern Cooperative Oncology Group scale (see Appendix). Patients must have fully recovered from toxicity of prior chemotherapy or radiation therapy.
Wilm's tumor and clear cell sarcoma\r\n * Patients with Wilms tumor or clear cell sarcoma will be eligible if relapse occurs following an autologous transplant or if the patient relapses following initial treatment, but is not eligible for an autologous transplant; patients who do not achieve a CR with initial therapy will also be eligible provided they can be rendered free of bulky disease as defined above
Neuroblastoma\r\n * Neuroblastoma patients will be eligible if relapse occurs following an autologous transplant or if the patient relapses following initial treatment, but is not eligible for an autologous transplant\r\n * Patients who do not achieve a CR with initial therapy will also be eligible provided they can be rendered free of bulky disease as defined above
Hodgkin disease (HD)\r\n * Patients with HD will be eligible if they fail to achieve a CR following conventional therapy\r\n * Patients who relapse following conventional therapy, but fail to achieve a second CR (or for any other reason cannot undergo autologous transplantation) will be eligible\r\n * Patients who relapse after an autologous transplant will be eligible
Participated or completed a GSK sponsored pazopanib study and remains eligible for continued treatment with pazopanib and lapatinib (if on combination therapy).
Patients with second malignancies in remission may be eligible if there is clinical evidence of disease stability for a period of greater than  months off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Patients maintained on long-term nonchemotherapy treatment, e.g., hormonal therapy, are eligible.
Patients with intracranial metastases, which have been treated by surgery or radiation therapy, may be eligible for study provided there is no evidence of active disease and no requirement for anticonvulsant therapy or steroids following treatment
Patients who at the time of enrollment, are willing and eligible to receive a stem cell transplant will not be eligible to participate in this study
Patient wishes to become pregnant\r\n* Note: patients who have undergone oocyte/embryo/ovarian tissue cryopreservation at breast cancer diagnosis and/or have a previous history of assisted reproductive technology (ART) are eligible
Patients with a motor, visual, or auditory handicap that prevents computer use (e.g., unresolved posterior fossa syndrome) are not eligible to participate in this trial
Patients with full-scale intelligence quotient (IQ) <  per previous testing OR existing diagnosis of/educational classification as a student with an intellectual disability are not eligible
Patients with multiple osseous sites are eligible; however should not treat more than  separate radiation treatment fields concurrently
Patients with prior treatment with IFN-gamma will be eligible, if they previously tolerated IFN-gamma, however patients must be off of IFN-gamma for at least three weeks before initiation of therapy on this trial
Breastfeeding mothers are not eligible
Infection requiring receipt of therapeutic oral or IV anti-microbials within  weeks of first study treatment; patients receiving routine anti-microbial prophylaxis (for dental extractions/procedures) are eligible
Patients with a prior diagnosis of hand-foot skin reaction are not eligible.
All ethnicities eligible
Patients having no reconstruction are eligible for the study
Eligible to receive, but not yet begun, aromatase inhibitor therapy
INCLUSION - STUDY : Cancer adult patients undergoing neurotoxic chemotherapy (agents including platinums, vinca alkaloids, taxanes, proteasome inhibitors and interferons) will be eligible to participate
Patients will be eligible for treatment of multiple synchronous osseous sites only if those sites can be included in no more than three treatment sites; for patients with painful metastases that are contiguous but do not fit into the definition of a site listed above, those patients will still be eligible but will be considered to have two treatment sites; for example, a patient with a lesion of T, T and T would be eligible but would be considered as two treatment sites since more than five consecutive vertebral bodies would be treated; these lesions could be treated with one field, even though the treatment is coded as two sites
Patients are eligible regardless of concurrent enrollment on protocol - (Predictors of Chemotherapy Toxicity in Older Adults)
Patients who did not enroll during their chemotherapy are still eligible to enroll during subsequent hormonal therapy or radiation as long as it within  months of diagnosis
Unstable psychiatric disease (psychotic disorders or major depression identified using Brief Psychiatry Rating Scale [unless stable in treatment for  months]) - smokers with stable psychiatric disease will be eligible
Radiation therapy, cytotoxic chemotherapy, and combined modality (both radiation and chemotherapy) used to treat other cancers or medical conditions and administered within  months prior to study enrollment; use of hydroxyurea or emergent leukapheresis (for cytoreduction of highly elevated white blood cell counts) is permissible; those AML patients who initially receive treatment with all-trans retinoic acid (ATRA) for presumptive diagnosis of APL but if APL is ruled out in final pathology will be eligible for the study
Treatable causes of fatigue have not been ruled out, at least by history and exam criteria, by the treating provider, such as uncontrolled pain, hypothyroidism, or insomnia; NOTE: if these are considered to be the primary cause for the patients fatigue then the patient is not eligible for this trial
Eligible metastatic lesions: ) a solitary spine metastasis; ) two contiguous spine levels involved; or ) a maximum of  separate sites; each of the separate sites may have a maximal involvement of  contiguous vertebral bodies; epidural compression (arrow) is eligible when there is a >=  mm gap between the spinal cord and the edge of the epidural lesion; a paraspinal mass =<  cm is allowed
Patients with a documented history of invasive fungal infection (IFI) within the previous  days are not eligible
Patients receiving treatment for an IFI are not eligible
Patients must have a firm diagnosis of cGvHD, in accordance with National Institutes of Health (NIH) guidelines; patients with overlap syndrome are also eligible, but patients with recurrent, late onset and/or persistent acute GvHD (alone) are not eligible
Patients scheduled to receive broad-spectrum prophylactic antibacterial therapy are ineligible; patients only receiving prophylaxis for Pneumocystis pneumonia (PCP) (trimethoprim [TMP]/sulfamethoxazole [SMX]) or encapsulated organisms (penicillin) are eligible
Within  days of enrollment:\r\n* Patients with a proven or probable invasive mold infection are not eligible\r\n* Patients with an incompletely treated invasive yeast infection are not eligible\r\n* Patients with an elevated galactomannan level (>= . index) within  days prior to time of enrollment (if performed) must have a full evaluation for invasive aspergillosis (including a negative chest computed tomography [CT] scan) during that time period to be eligible for enrollment
Patients receiving treatment for an IFI are not eligible
Eligible after  months of completing all their active cancer treatment with the exception of long-term hormonal treatments or trastuzumab.
Eligible to receive AHT (tamoxifen or an aromatase inhibitors [AI]) for the first time
Adult patients with hematologic malignancy admitted to Massachusetts General Hospital (MGH) HSCT are eligible for the study
Patients with history of liver transplantation may be eligible for the dose expansion cohorts (parts A and B) of this study provided all eligibility criteria are met and provided the subject has not had any episodes of acute rejection or serious opportunistic infection within  months from enrollment\r\n* Certain immunosuppressive agents such as tacrolimus and sirolimus are prohibited thus liver transplant patients who require these medications for immunosuppression are not eligible\r\n* Patients receiving everolimus at immunosuppressive dosages are eligible
An international normalized ratio (INR) =< . (patients who are therapeutically anticoagulated for unrelated medical conditions such as atrial fibrillation and whose antithrombotic treatment can be withheld for operation will be eligible)
Arm C and C: SCNSL patients do not require one prior CNS directed treatment; newly diagnosed SCNSL patients are eligible as long as their systemic disease has been treated and does not require any active treatment
Patients with uncontrolled major psychiatric disorders, such as major depression or psychosis, will not be eligible for this trial; patients with a history of depression or anxiety who are stable on or off psychiatric medications will be eligible
Patients for whom there is only one good surgical option or any other clinical/nonclinical reason for which the surgeon determines the patient is not eligible for the study
Presence of extensive skeletal metastases defined as more than five () sites of bony disease, or any symptomatic site of disease in the spine, hip, or femur; Note that, patients with more than five bony sites may be deemed eligible at the discretion of the attending oncologist
Patients who are not eligible to receive SCT with cyclophosphamide and total body irradiation (TBI) conditioning because they do not meet transplant criteria are also not eligible for this phenylephrine study
General exclusion criteria for transplant include:\r\n* Patients who have angina and/or congestive heart failure requiring treatment, or who have had a myocardial infarction within the past year\r\n* Patients who have had any complication that makes the risk of death during transplantation from non-malignant causes greater than the risk of relapse\r\n* Patients who have any active infection; if the infection is successfully treated, the patient may be reconsidered for transplantation at a later date\r\n* Patients with diabetes who are not controlled by medical management will be ineligible\r\n* Psychiatric illness requiring psychiatric counseling or medical intervention other than antidepressant medications may make an individual ineligible and will be considered on a case-by-case basis\r\n* Psychosocial assessment by the bone marrow transplant team may identify individuals for whom this form of therapy may be contraindicated; these decisions will be based upon estimated adequacy of patient support systems and prediction of patients compliance with medications, required diagnostic procedures, and/or follow-up care\r\n* Patients who have an ECOG performance status of greater than \r\n* Patients who have decreased pulmonary function due to any disorder as demonstrated by a diffusion capacity of less than % of predicted, a FEV of less than % of predicted, or a PO of less than mmHg on pulmonary function testing\r\n* Patients who have a resting ejection fraction of less than %\r\n* Patients who have renal disease as demonstrated by a serum creatinine clearance of greater than . mg/dL and/or a creatinine clearance of less than  mL/min\r\n* Patients who are pregnant or breast feeding at the time of admission for conditioning
Patients with tumors adjacent to a vertebral body are eligible as long as all gross disease can be encompassed in the radiation boost field; the boost volume must be limited to < % of the ipsilateral lung volume
Both heterosexual and same sex couples will be eligible
All diagnoses will be eligible
Treatment may be given to eligible patients with a single or multiple infections; patients with multiple infections with one or more reactivation and one or more controlled infection are eligible to enroll
Patients who have had local genotyping are eligible, regardless of the local result
Individuals who are cognitively impaired are eligible for the study and consent for participation must be given by a legal authorized representative or parent; pregnant women are eligible for the study
Patients aged - with no evidence of a colonoscopy within  years or fecal testing within  months, and no history of colorectal disease will be eligible to receive a mailed FIT.
Patients who have undergone a prior tubal ligation will be eligible
Subjects deemed potentially eligible by their treating physicians will be screened for enrollment after d+ from transplantation
Considered eligible for Ohio Expanded Food and Nutrition Education Program (EFNEP) income guidelines
Women with an intact cervix (patients who have undergone previous loop electrosurgical excision procedure [LEEP], cone and/or cryotherapy are eligible)
Sexually active women of all ethnicities and races with an intact cervix are eligible for this trial
Patient is diagnosed with hematological malignancies including PTCL and CTCL and are eligible for treatment with a dose of  mg/m^
All TP germline mutation positive adult patients will be eligible for this study; all patients must have a documented TP germline mutation
Subjects who work night shifts are not eligible
Patients must have histologically confirmed, newly diagnosed or recurrent from a previously treated early stage lung cancers that are locally confined, non-small cell lung cancers that are considered unresectable and for which chemoradiation will be considered definitive therapy; patients with recurrent cancer that is amendable for chemoradiation can be eligible only if patients with prior lobectomy for stage I cancer had not had adjuvant chemotherapy, and more than  weeks have elapsed from surgery to allow for wound healing; patients who recur from prior X-ray therapy (XRT) or stereotactic body radiation therapy (SBRT) will not be eligible
Patients will have to undergo mutational testing for Isocitrate dehydrogenase  (IDH) on a tumor specimen before entering study. Patients are eligible for Arm C regardless of their IDH mutational status.
Patient not eligible for sequential MRI evaluations are not eligible for this study.
Patients who have multicentric disease
Eligible for BCT based on clinical examination, mammography and, if standard practice at a given institution, ultrasound and/or tomogram; women who cannot be appropriately selected for BCT based on these standard imaging studies, and for whom additional imaging is recommended to clarify local disease extent, will not be eligible for this trial; for patients who have neoadjuvant therapy, eligibility for BCT is determined at completion of therapy; repeat mammogram +/- ultrasound (US) will be required at completion of neoadjuvant chemotherapy to determine eligibility for BCT
Patients with local or regional nodal disease are eligible
PHASE I: Eligible patients include patients with histologically proven neuroendocrine tumors (paraganglioma, PHEO [pheochromocytoma], or well differentiated neuroendocrine tumor [NET] of the lung or gastrointestinal [GI] system) or neuroblastoma (NB); patients, who have NB, the diagnosis must be in accordance with the International Criteria, i.e., either histopathology or bone marrow involvement; patients must be able to undergo PET scan without sedation
 consecutive consenting patients presenting to The Ohio State University College of Dentistry for routing dental care will be recruited; adult patients presenting to the screening clinic for initial oral evaluation will be eligible to participate
Patients who are pregnant or lactating or who suspect they might be pregnant are not eligible; a serum pregnancy tests will be obtained - hours prior to the initial PET scan in female patients who are not postmenopausal or surgically sterile
Patients with local or regional nodal disease are eligible
Patients must be eligible for breast-conserving therapy (BCT) based on clinical examination and mammography; if ultrasound is performed, findings must also be consistent with eligibility for BCT
Patients with cTN-M or cT-NxM will be considered eligible for participation
ADULT PATIENTS:
PEDIATRIC PATIENTS:
Cannot eat normal table food by mouth; NOTE: patients with any form of feeding tube or a swallowing disorder are not eligible
Have taken fish oil, another dedicated n- supplement, or SH seed from another source within the last  days; patients on multivitamins that contain n- are eligible
Patients deemed inoperable (no scheduled surgery) are eligible for this trial, as they could be surgical candidates after treatment with vemurafenib; inoperable patients must be naive to therapies targeting the MAPK pathway
All diseases that are indications for allogeneic BMT at Stanford University will be eligible for participation in this study
No limitations on prior therapy for eligibility; eligible patients must be receiving their first allogeneic BMT
Consent both to provide data themselves and to assist in identifying eligible patients for recruitment to the trial
While we are focusing on recruitment of clinicians who treat breast, prostate, or colorectal cancers, any eligible patients of the clinicians (e.g., a testicular cancer patient) will be approached for potential participation in the study
Patients eligible for this companion sample collection protocol sample collection protocol must meet all inclusion in CLEEA.
Patients are eligible if they have been in stable dasatinib induced CMR for a minimum of nine months, documented by at least three assessments, conducted  - . months apart, at a local lab.
Additional Criteria for Patients Eligible to Restart Dasatinib
Patients who are progressing on current fulvestrant therapy (patients who have had\n             fulvestrant therapy in the past and were subsequently treated with other therapies or\n             those who are starting fulvestrant as their next line of ET are eligible for the\n             study).
